Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil:: results of a pilot study

被引:41
作者
Ballarin, Jose [1 ]
Poveda, Rafael [1 ]
Ara, Jordi [1 ]
Perez, Laurea [1 ]
Calero, Francesca [1 ]
Grinyo, Josep M. [1 ]
Romero, Ramon [1 ]
机构
[1] Hosp Vic Barcelona, Barcelona, Spain
关键词
membranous nephropathy; treatment; steroids; tacrolimus; mycophenolate mofetil; association;
D O I
10.1093/ndt/gfm366
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Membranous nephropathy is a common cause of nephrotic syndrome (NS) in adults. Its treatment is still under debate. Methods. We report our experience in a pilot study using initially low doses of steroids and tacrolimus (Tac). After 3 months of treatment, mycophenolate mofetil (MMF) was added if the proteinuria was higher than 1g/day. Results. In accordance with this standard, 21 patients entered the study. A proteinuria level lower than 1g/day was reached at month 3 of therapy with steroids and Tac in 11 patients. These patients continued this treatment for 12 months. MMF was added in nine cases after the third month and triple therapy was maintained for 12 more months. Two patients were withdrawn because of side effects. At the end of the treatment, remission of the NS was present in 15 out of all the patients (71.4). Remission of the NS was complete in eight (53.3) patients and partial in seven (46.7) others. The remaining four patients did not respond. There were no significant changes in renal function. At a mean time of 23.1 months after treatment was discontinued, 11 (73.3) patients had relapsed. Conclusions. In this trial, treatment with tacrolimus showed a good efficacy but a high relapse rate when it was discontinued.
引用
收藏
页码:3196 / 3201
页数:6
相关论文
共 49 条
[1]   Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: Results at 2 years [J].
Ahsan, N ;
Johnson, C ;
Gonwa, T ;
Halloran, P ;
Stegall, M ;
Hardy, M ;
Metzger, R ;
Shield, C ;
Rocher, L ;
Scandling, J ;
Sorensen, J ;
Mulloy, L ;
Light, J ;
Corwin, C ;
Danovitch, G ;
Wachs, M ;
VanVeldhuisen, P ;
Salm, K ;
Tolzman, D ;
Fitzsimmons, WE .
TRANSPLANTATION, 2001, 72 (02) :245-250
[2]   Use of mycophenolate mofetil in autoimmune and renal diseases [J].
Appel, GB ;
Radhakrishnan, J ;
Ginzler, EM .
TRANSPLANTATION, 2005, 80 (02) :S265-S271
[3]   Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile [J].
Artz, MA ;
Boots, JMM ;
Ligtenberg, G ;
Roodnat, JI ;
Christiaans, MHL ;
Vos, PF ;
Moons, P ;
Borm, G ;
Hilbrands, LB .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :937-945
[4]   Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia [J].
Atcheson, BA ;
Taylor, PJ ;
Kirkpatrick, CMJ ;
Duffull, SB ;
Mudge, DW ;
Pillans, PI ;
Johnson, DW ;
Tett, SE .
THERAPEUTIC DRUG MONITORING, 2004, 26 (03) :284-286
[5]   Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency [J].
Branten, AJW ;
Reichert, LJM ;
Koene, RAP ;
Wetzels, JFM .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1998, 91 (05) :359-366
[6]   A CONTROLLED TRIAL OF CYCLOSPORINE IN PATIENTS WITH PROGRESSIVE MEMBRANOUS NEPHROPATHY [J].
CATTRAN, DC ;
GREENWOOD, C ;
RITCHIE, S ;
BERNSTEIN, K ;
CHURCHILL, DN ;
CLARK, WF ;
MORRIN, PA ;
LAVOIE, S .
KIDNEY INTERNATIONAL, 1995, 47 (04) :1130-1135
[7]   Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial [J].
Cattran, DC ;
Appel, GB ;
Hebert, LA ;
Hunsicker, LG ;
Pohl, MA ;
Hoy, WE ;
Maxwell, DR ;
Kunis, CL .
KIDNEY INTERNATIONAL, 2001, 59 (04) :1484-1490
[8]   Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications [J].
Cattran, DC ;
Pei, Y ;
Greenwood, CMT ;
Ponticelli, C ;
Passerini, P ;
Honkanen, E .
KIDNEY INTERNATIONAL, 1997, 51 (03) :901-907
[9]   Mycophenolate mofetil treatment for primary glomerular diseases [J].
Choi, MJ ;
Eustace, JA ;
Gimenez, LF ;
Atta, MG ;
Scheel, PJ ;
Sothinathan, R ;
Briggs, WA .
KIDNEY INTERNATIONAL, 2002, 61 (03) :1098-1114
[10]   Review of major clinical trials with mycophenolate mofetil in renal transplantation [J].
Ciancio, G ;
Miller, J ;
Gonwa, TA .
TRANSPLANTATION, 2005, 80 (02) :S191-S200